

- Daclatasvir is a non-structural protein 5A (NS5A) inhibitor with activity against hepatitis C virus (HCV) genotypes 1 to 6 in vitro, and asunaprevir is a non-structural protein 3 (NS3) protease inhibitor with activity against genotypes 1, 4, 5, and 6.
- This pre-clinical study evaluates potential options for the re-treatment of HCV genotype 1b-infected patients who have failed combination therapy with daclatasvir plus asunaprevir using in vitro HCV replicon elimination assays.
- At clinically relevant drug trough concentrations, all-oral regimens of daclatasvir plus asunaprevir plus beclabuvir ( $\pm$  ribavirin), daclatasvir plus asunaprevir, beclabuvir, and sofosbuvir demonstrated greatest efficiency in HCV clearance in vitro.
- The results of the study highlight a number of potential all-oral treatment options for patients who do not achieve a sustained virologic response following therapy with daclatasvir plus asunaprevir. These results require further evaluation in clinical studies.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Bristol-Myers Squibb, Wallingford, USA. Medical writing assistance for this study was provided by Andrew Street, ArticulateScience, Manchester, UK. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).